Perspectives of Ketamine Use in COVID-19 Patients.
J Korean Med Sci
; 36(4): e28, 2021 Jan 25.
Article
in English
| MEDLINE | ID: covidwho-1048950
Semantic information from SemMedBD (by NLM)
1. COVID-19 PROCESS_OF Patients
2. Stres PROCESS_OF C0870668
3. Physical impairment PROCESS_OF hospitalized patients
4. Depressive disorder COEXISTS_WITH Pulmonary Valve Insufficiency
5. Anesthesia procedures TREATS Depressive disorder
6. Pharmaceutical Preparations TREATS Feeling suicidal (finding)
7. COVID-19 PROCESS_OF Patients
8. Stress, Psychological PROCESS_OF hospitalized patients
9. Physical impairment PROCESS_OF hospitalized patients
10. Depressive disorder COEXISTS_WITH Pulmonary Valve Insufficiency
11. Anesthesia procedures TREATS Depressive disorder
12. Pharmaceutical Preparations TREATS Feeling suicidal (finding)
ABSTRACT
Hospitalized coronavirus disease 2019 (COVID-19)-infected patients suffer from both physical impairments and mental stress. Respiratory insufficiency and cardiovascular disturbances require most of the intensive care interventions, but they are also accompanied by depressive conditions, sadness and fear of dying. Sedatives are mostly respiratory and cardiovascular depressants and do not provide resistance to the pro-inflammatory burst induced by the virus. Ketamine is a unique and safe drug that enables well-controlled sedation and anesthesia, attenuates depression and mitigates suicidal thoughts, without depressing respiratory or cardiovascular mechanics. This brief communication highlights the benefits potentially provided by ketamine to patients hospitalized for COVID-19 infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Stress, Psychological
/
Depression
/
COVID-19
/
Ketamine
Limits:
Humans
Language:
English
Journal:
J Korean Med Sci
Journal subject:
Medicine
Year:
2021
Document Type:
Article
Affiliation country:
Jkms.2021.36.e28